Company Information

Our Mission

We make the paradigm shift in biomedicine with the advanced technology for analysis and synthesis of glycans and achieve the world-leading fundamental technology.

Company Information

Company Name
(Abbreviation)
GlycoBiomarker Leading Innovation Co. Ltd.
(GL-i)
Business Outline Commercialization of glycan-related clinical diagnostics and pharmaceutical products using unique technologies for glycan synthesis and analysis
Location [Head office and Laboratory]
2-12, AIST Tsukuba Central 2, 1-1-1, Umezono, Tsukuba, Ibaraki, 305-8568 Japan

[Tsukuba Second Laboratory]
Building G, TCI, 2-1-6 Sengen, Tsukuba, Ibaraki, 305-0047 Japan

[Tsukuba Third Laboratory]
2-1C, AIST Tsukuba Central 2, 1-1-1, Umezono, Tsukuba, Ibaraki, 305-8568 Japan
Phone & Facsimile +81-29-886-9117
Founding Date March 3, 2015
Number of Employees
(As of June 1, 2017)
17
Main Bank Mito Shinkin Bank, Joyo Bank, Ltd., Sumitomo Mitsui Banking Co.
Related Organization National Institute of Advanced Industrial Science and Technology (AIST)

Executives

President, Chief Executive Officer Kazuyuki Takeo
Director, Chief Technology Officer Atsushi Kuno
Director, Chief Financial Officer Masayuki Ushida
Corporate Auditor Toru Takahashi

Corporate History

March 2015 Establishment of company
July 2016 Start collaborative research with Sysmex Co. (Immunological test reagents)
August 2016 Establishment of the Tokyo Office
November 2016 Establishment of the Second Laboratory
February 2017 Relocation of the Tokyo Office
April 2017 Establishment of the Third Laboratory

Founding Prospectus


We actualize the research outcome related to the glycoprotein analysis technology that was developed in the National Institute of Advanced Industrial Science and Technology (AIST). We develop diagnostic agents for early detection of disease and prediction of prognosis based on the glycans exhibiting altered constituents along with onset and progression of disease. Glycans are present on surfaces of cells and most of proteins. The constituents of glycans change along with the state of cells secreting proteins changes. Owing to this feature, glycans can be used to measure the state of disease. In 2013, Sysmex Corporation marketized a glycobiomarker for liver fibrosis (laboratory testing technology) that was developed by AIST, Research Center for Medical Glycoscience (RCMG), and the assay kit was approved for health insurance coverage by Pharmaceuticals and Medical Devices Agency of Japan. This successful practical realization is one of the achievements resulting from more than 10 years of RCMG’s research activity. GL-i was established to realize subsequent cases of technical transfer for laboratory testing based on the platform technology for glycoprotein analysis. Many potential candidates are being found in RCMG. In the future we will lead the field of glycan-related medicine in both laboratory testing and clinical medicine with our unique approach fully utilizing the characteristics of glycans.

March 3, 2015

President and CEO

Kazuyuki Takeo

Page Top